3-Hydroxymorphinan, a metabolite of dextromethorphan, protects nigrostriatal pathway against MPTP-elicited damage both in vivo and in vitro. - sprookjes - yvandenbroek - TriplyDB

3-Hydroxymorphinan, a metabolite of dextromethorphan, protects nigrostriatal pathway against MPTP-elicited damage both in vivo and in vitro.

3-Hydroxymorphinan, a metabolite of dextromethorphan, protects nigrostriatal pathway against MPTP-elicited damage both in vivo and in vitro.

http://www.wikidata.org/entity/Q34586750

about

Inhibition of IkappaB kinase-beta protects dopamine neurons against lipopolysaccharide-induced neurotoxicity Endogenous dynorphin protects against neurotoxin-elicited nigrostriatal dopaminergic neuron damage and motor deficits in mice Automated imaging system for fast quantitation of neurons, cell morphology and neurite morphometry in vivo and in vitro.Macrophage antigen complex-1 mediates reactive microgliosis and progressive dopaminergic neurodegeneration in the MPTP model of Parkinson's disease.Adulthood Exposure to Lipopolysaccharide Exacerbates the Neurotoxic and Inflammatory Effects of Rotenone in the Substantia Nigra Resveratrol protects dopamine neurons against lipopolysaccharide-induced neurotoxicity through its anti-inflammatory actions.Clozapine protects dopaminergic neurons from inflammation-induced damage by inhibiting microglial overactivation.Naloxone inhibits immune cell function by suppressing superoxide production through a direct interaction with gp91phox subunit of NADPH oxidase Oxidative stress and microglial cells in Parkinson's disease Reactive oxygen species and inhibitors of inflammatory enzymes, NADPH oxidase, and iNOS in experimental models of Parkinson's disease.A placebo-controlled trial of dextromethorphan as an adjunct in opioid-dependent patients undergoing methadone maintenance treatment Neuroinflammation is a key player in Parkinson's disease and a prime target for therapy.Neuropsychopharmacological understanding for therapeutic application of morphinans Apocynin prevents mitochondrial burdens, microglial activation, and pro-apoptosis induced by a toxic dose of methamphetamine in the striatum of mice via inhibition of p47phox activation by ERK Resveratrol Produces Neurotrophic Effects on Cultured Dopaminergic Neurons through Prompting Astroglial BDNF and GDNF Release.Fluoxetine protects neurons against microglial activation-mediated neurotoxicity Inflammation in patients with schizophrenia: the therapeutic benefits of risperidone plus add-on dextromethorphan Role of oxidative stress in methamphetamine-induced dopaminergic toxicity mediated by protein kinase Cδ.Non-mammalian animal models of Parkinson's disease for drug discovery.Resveratrol promotes neurotrophic factor release from astroglia.The neuroprotective disease-modifying potential of psychotropics in Parkinson's disease.The MPTP Story.Ginsenoside Re rescues methamphetamine-induced oxidative damage, mitochondrial dysfunction, microglial activation, and dopaminergic degeneration by inhibiting the protein kinase Cδ gene.Dextromethorphan attenuated inflammation and combined opioid use in humans undergoing methadone maintenance treatment.Risperidone enhances the vulnerability to stroke in hypertensive rats.Icariin Reduces Dopaminergic Neuronal Loss and Microglia-Mediated Inflammation in Vivo and in Vitro.N-Methyl, N-propynyl-2-phenylethylamine (MPPE), a Selegiline Analog, Attenuates MPTP-induced Dopaminergic Toxicity with Guaranteed Behavioral Safety: Involvement of Inhibitions of Mitochondrial Oxidative Burdens and p53 Gene-elicited Pro-apoptotic C Ginsenoside Re protects methamphetamine-induced dopaminergic neurotoxicity in mice via upregulation of dynorphin-mediated κ-opioid receptor and downregulation of substance P-mediated neurokinin 1 receptor.Liposomal melatonin rescues methamphetamine-elicited mitochondrial burdens, pro-apoptosis, and dopaminergic degeneration through the inhibition PKCδ gene.Tetrahydroxystilbene Glucoside Produces Neuroprotection against 6-OHDA-Induced Dopamine Neurotoxicity.Combination Treatment of Icariin and L-DOPA Against 6-OHDA-Lesioned Dopamine Neurotoxicity.Dual modulation on glial cells by tetrahydroxystilbene glucoside protects against dopamine neuronal loss.NMDA antagonists for treating the non-motor symptoms in Parkinson's disease.

P2860

Q28577454-834B84B5-E0B3-4C94-9E33-19ADEBF4F3CC Q30523813-EE9FC3BB-F06B-4E84-9A5F-6C9C9BF12753 Q30537879-09158F9C-882A-4520-946F-B271BD805CE7 Q33112256-2CF8D08D-7F19-44A9-BA4C-A4C36FF79285 Q33646907-8297A771-F1D1-4662-B5FD-FE7343941925 Q34127988-61B7626E-3ADB-4E15-B94F-AB678FD567F4 Q34631859-F58DDD1F-72A1-4B4D-8F4E-E9870F34E68B Q35833987-59C59D2F-814D-498B-BF32-C6787C6DD672 Q35876266-E49B66F4-45DB-4C83-9A8C-7EE10B52C42C Q35942562-1734A6C3-F799-41FB-A83E-BC2844AA77B9 Q35965884-BBF7A9A0-084C-4806-ADCE-4159635F9948 Q36085162-D0F58315-3ECD-4FCB-92EA-8A4730E27CFC Q36102944-17F7B6F5-228C-4C68-A11B-EB7E85B0B79E Q36476821-509533A1-9052-4BFF-B7CD-C5217217582A Q36477181-28A3DED6-8BD2-473D-BCD4-ECCA87D94BF1 Q36717735-22CC9B77-8265-47F1-9C06-C09E43DECFE8 Q36725461-B7358ADF-90D4-4925-8AC8-8C67FD934120 Q37661270-7E4F23CE-E92B-4075-9C60-D71F390079D0 Q38028522-A4D42479-CDCF-4165-897F-024ED419F2E4 Q39300523-041D5F40-0897-4327-98FD-7D9310838352 Q40299879-5C59A6B3-CF7A-40C9-BD01-8ACDEDC625AC Q41825283-A004C124-2DE1-466B-8160-187EEDAD8686 Q42707394-290811C2-911D-4C9C-8D34-667E5ED4C0C1 Q44336042-BAA13186-CF69-4D99-A177-518A6B6929FD Q46983744-8992E716-85AD-4A20-AFF8-6AA74A77CDBA Q47836628-BAC6C501-9930-46AA-A752-4618D1B5B5F1 Q48451343-3534808F-31C0-4CED-93DE-AC18E7E7A200 Q53082241-A3378D82-67A6-4C00-B0DC-AB08C1DCA462 Q53250515-940909B5-6440-4F05-8D7D-300BE5931DC1 Q54119424-E773C129-E9E2-449C-B2A2-D604B046C477 Q55118987-E734F4D9-F35E-4C6F-A8BF-880085F43994 Q55308535-83661B08-D0C8-4976-995B-95873D820F5C Q55474333-1EDC78BF-82F9-4EA1-9942-A6E4F9CD6447

P2860

3-Hydroxymorphinan, a metabolite of dextromethorphan, protects nigrostriatal pathway against MPTP-elicited damage both in vivo and in vitro.

http://www.wikidata.org/entity/Q34586750

description

2006 nî lūn-bûn

@nan

2006 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

3-Hydroxymorphinan, a metaboli ...... age both in vivo and in vitro.

@ast

3-Hydroxymorphinan, a metaboli ...... age both in vivo and in vitro.

@en

3-Hydroxymorphinan, a metaboli ...... age both in vivo and in vitro.

@nl

type

label

3-Hydroxymorphinan, a metaboli ...... age both in vivo and in vitro.

@ast

3-Hydroxymorphinan, a metaboli ...... age both in vivo and in vitro.

@en

3-Hydroxymorphinan, a metaboli ...... age both in vivo and in vitro.

@nl

prefLabel

3-Hydroxymorphinan, a metaboli ...... age both in vivo and in vitro.

@ast

3-Hydroxymorphinan, a metaboli ...... age both in vivo and in vitro.

@en

3-Hydroxymorphinan, a metaboli ...... age both in vivo and in vitro.

@nl

P1433

Q34586750-78C2269E-F5BE-4CB6-A0C2-8B8B41F6FCAB

P1476

Q34586750-8052578A-EB8F-476A-B37E-244F0119D983

P2093

Q34586750-0EABCF90-6019-410F-906B-97BCDBC545B3

Q34586750-23643710-4018-44C9-972C-A6522CB9ACE4

Q34586750-38366F00-BB80-4A8D-92F8-1255CDCA3446

Q34586750-52ACAE5E-BE84-4234-84A0-456A73BC5B2F

Q34586750-6A1798AD-F7AD-4249-B52B-2083D38BE7EA

Q34586750-8D25199F-1FBE-4CFE-8E6D-0FABA4927987

Q34586750-9F9B528B-2331-4C5C-8A42-8A62D5682251

Q34586750-BD4854A5-F0BE-497D-B3F6-0E30769CE05E

Q34586750-C3437E30-1C92-4DB4-81BA-8D8039FF76F5

Q34586750-C74AE1C6-0B10-485D-9973-D00903CE86E5

P304

Q34586750-45F104F7-E9D3-4E7C-9208-3D59C24E9095

P31

Q34586750-9552273A-D54A-4762-83EF-C0F9B58C428A

P356

Q34586750-6101AAFD-3668-4CA0-890D-4C58E482378D

P407

Q34586750-D5B4C9F0-7250-4152-81B1-00C3E60274E5

P433

Q34586750-A710FC02-9907-4051-91D9-8B6762395A61

P478

Q34586750-D8790FA1-4E3A-465A-9C96-FE129158DC1A

P50

Q34586750-CECCC04E-6630-41B5-A99B-A631DDE28F93

P577

Q34586750-2ECEC78F-2D5B-4685-80D4-DAB57F5FA683

P5875

Q34586750-D3C13E8B-4CA9-4F4E-82C2-C4C867C87231

P698

Q34586750-C3D6D683-AEBC-4C15-91E3-942B3100D2ED

P356

P1433

P1476

3-Hydroxymorphinan, a metaboli ...... mage both in vivo and in vitro

@en

P2093

Eun-Joo Shin

http://www.w3.org/2001/XMLSchema#string

Hao Pang

http://www.w3.org/2001/XMLSchema#string

Hyoung-Chun Kim

http://www.w3.org/2001/XMLSchema#string

Myung-Bok Wie

http://www.w3.org/2001/XMLSchema#string

Phil Ho Lee

http://www.w3.org/2001/XMLSchema#string

Seong-Jin Kim

http://www.w3.org/2001/XMLSchema#string

Tongguang Wang

http://www.w3.org/2001/XMLSchema#string

Wanqin Zhang

http://www.w3.org/2001/XMLSchema#string

Wei Zhang

http://www.w3.org/2001/XMLSchema#string

Wen-Hsin Huang

http://www.w3.org/2001/XMLSchema#string

P304

2496-2511

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1096/FJ.06-6006COM

http://www.w3.org/2001/XMLSchema#string

P407

P433

14

http://www.w3.org/2001/XMLSchema#string

P478

20

http://www.w3.org/2001/XMLSchema#string

P50

Jau-Shyong Hong

P577

2006-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6655821

http://www.w3.org/2001/XMLSchema#string

P698

17142799

http://www.w3.org/2001/XMLSchema#string